Rolapitant Is a Reversible Inhibitor of CYP2D6

• Published in: Drug metabolism and disposition 2019-06, Vol.47 (6), p.567-573
• Main Authors: Glass, Sarah M, Leddy, Sabrina M, Orwin, Michael C, Miller, Garret P, Furge, Kyle A, Furge, Laura Lowe
• Format: Article
• Language: English
• Subjects: Binding; Catalytic Domain - physiology; Chemotherapy; Computer simulation; CYP2D6 protein; Cytochrome P-450 CYP2D6 - metabolism; Cytochrome P-450 CYP2D6 Inhibitors - therapeutic use; Cytochrome P450; Deactivation; Dextromethorphan; Dextromethorphan - therapeutic use; Drug interaction; Drug interactions; Drug Interactions - physiology; Ethanolamines - therapeutic use; Humans; Inactivation; Inhibition; Inhibitors; Interaction models; Metabolism; Metabolites; Molecular dynamics; NADP; Nausea; Spiro Compounds - therapeutic use; Substrates; Time dependence; Vomiting
• ISSN: 0090-9556; 1521-009X
• DOI: 10.1124/dmd.118.085928

Rolapitant [(Varubi), 5 ,8 )-8-[[(1 )-1-[3,5 bis(trifluoromethyl phenyl]ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one] is a high-affinity NK1 receptor antagonist that was approved in September 2015 as a treatment for nausea and vomiting caused by chemotherapy. In vivo rolapitant moderately inhibits CYP2D6 for at least 7 days after one 180 mg dose. Due to the long inhibition time, we investigated rolapitant as a possible mechanism-based inactivator of CYP2D6. Rolapitant docked in the active site of CYP2D6 and displayed type I binding to CYP2D6 with a value of 1.2 ± 0.4 M. However, in NADPH-, time-, and concentration-dependent assays of CYP2D6 activity, no evidence for mechanism-based inactivation and no metabolites of rolapitant were observed. Stopped-flow binding studies yielded a / ( ) value of 6.2 M. The IC value for rolapitant inhibition of CYP2D6 activity was 24 M, suggesting that inhibition is not due to tight binding of rolapitant to CYP2D6. By Lineweaver-Burk analysis, rolapitant behaved as a mixed, reversible inhibitor. The values of 20 and 34 M were determined by Dixon analysis, with bufuralol and dextromethorphan as reporter substrates, respectively, and drug-drug interaction modeling did not predict the reported in vivo inhibition. The interaction of rolapitant with CYP2D6 was also examined in 1 microsecond molecular dynamics simulations. Rolapitant adopted multiple low-energy binding conformations near the active site, but at distances not consistent with metabolism. Given these findings, we do not see evidence that rolapitant is a mechanism-based inactivator. Moreover, the reversible inhibition of CYP2D6 by rolapitant may not fully account for the moderate inhibition described in vivo.